Research on boosting antiviral immunity through therapeutic vaccination has revealed that recombinant glycoprotein vaccines are well-tolerated, safe, and immunogenic. CD BioGlyco is dedicated to the design, expression, synthesis, and production of recombinant glycoprotein vaccines, providing customers with a one-stop custom solution.

Recombinant Glycoprotein Vaccine

Glycans play very significant roles in life activities. Glycosylation affects many aspects of proteins such as folding, stability, signal transduction, biological activity, and immunogenicity. Most recombinant glycoprotein vaccines can improve the immunogenicity and potency of proteins by extending their half-life and thus improving their solubility and stability, and the immune system will produce antibodies against the recombinant glycoproteins.

At present, recombinant glycoprotein vaccines have been increasingly studied and have promising potential for development. The following are several examples of synthetic glycoprotein vaccine: recombinant glycoprotein vaccine against herpes simplex virus type 2 (HSV-2), recombinant herpes zoster vaccine (RZV) containing a single varicella-zoster virus (VZV) glycoprotein and an adjuvant system, recombinant glycoprotein vaccines for children infected with human immunodeficiency virus type 1 (HIV-1), vaccine glycoprotein B (gB) for congenital cytomegalovirus (CMV) infection and a new COVID-19 vaccine developed using a long-acting recombinant glycoprotein.

Fig.1 Current method for the production of conjugate vaccines and in vivo biosynthesis. (Ihssen, 2010)

Our Solutions

To enhance the stability of vaccines and to produce long-lasting immune protection, CD BioGlyco has established a highly specialized and advanced platform and multiple innovative solutions for the design, expression, evaluation, and production of recombinant glycoprotein vaccines.

• The target antigen gene will be cloned onto an expression vector followed by transforming the constructed expression protein vector into glyco-engineered bacteria, yeast systems, mammalian or insect cells. Under certain induction conditions, a large number of recombinant glycoproteins will be produced and then purified.
• A comprehensive vaccine efficacy evaluation system has been established. In the first stage, immunogenicity will be tested in animals and their immunological properties will be examined. In the second stage, safety detection will be carried out in higher animals and then the first stage clinical trials will be carried out in healthy participants.

Advantages of Us

• High purity and better safety
• Comprehensive evaluation system for vaccine effectiveness
• Induction of long-term immune memory
• Customer-oriented service

CD BioGlyco has the most advanced technology platform and scientific expertise in the field of glycobiology including vaccine development, allowing our clients to accelerate their research. If you have a demand for our services, please feel free to contact us and we will assist you in the process of developing recombinant glycoprotein vaccines.

References:

1. Heineman, T.C.; et al. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Current Opinion in Immunology. 2019, 59:42-48.
2. Ihssen, J.; et al. Production of glycoprotein vaccines in Escherichia coli. Microbial Cell Factories. 2010, 9(1):61-61.